SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the completion of its previously disclosed merger with Conatus Pharmaceuticals Inc. The
Location: United States, California, San Diego
Total raised: $80M
Investors 3
Funding Rounds 3
| Date | Series | Amount | Investors |
| 12.04.2011 | Series B | $32.5M | - |
| 11.02.2011 | Series B | $20M | - |
| 11.05.2007 | - | $27.5M | - |
Mentions in press and media 11
| Date | Title | Description |
| 22.03.2019 | Little Conatus' Novartis-partnered liver drug suffers third straight defeat, but CEO Mento is still holding out hope | Little Conatus’ Novartis-partnered liver drug is one step closer to the scrap heap, with its third mid-stage failure. The Swiss drugmaker handed the San Diego-based biotech $50 million upfront and an injection of confidence... |
| 08.01.2015 | Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan | San Diego, CA — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that aggregate top-line results from three pharmacokinetic (PK) and pharmacodynamic (PD) clinical trials in organ-impaired patients provided confirmatory support for... |
| 30.10.2013 | Which venture capital firm’s healthcare investment picks secured the most IPOs? | I won’t get into Aratana Therapeutics (Nasdaq: PETX) because the biopharmaceutical company develops treatments for animals. Acceleron Pharma: (Nasdaq: XLRN) raised $96.7 million after it priced at the high end of its share price range. The ... |
| 13.04.2011 | Conatus Pharmaceuticals Receives $7.5M in Follow-On Investment | Conatus Pharmaceuticals Inc... Take 1 minute to subscribe and you'll get this story immediately, plus: Already a subscriber? Sign in 52 weekly issues Subscriber-only digital content every business day, plus full access to SDBJ.com archives ... |
| 12.04.2011 | Conatus Pharmaceuticals Raises $7.5M; Closes $32.5M Series B Financing | Conatus Pharmaceuticals Inc., a San Diego, CA-based biopharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology, has received an additional $7.5m investment by MPM Capital, closi... |
| 14.02.2011 | Conatus Pharmaceuticals Raises $20M | San Diego-based Conatus Pharmaceuticals said Friday afternoon that it has closed a $20M, Series B funding round. The firm, which is developing treatments for Hepatitis C, said the funding was led by AgeChem Venture Fund, and also included A... |
| 14.02.2011 | Conatus Pharmaceuticals Raises $20 Million | SAN DIEGO – Conatus Pharmaceuticals Inc. announced the closing of a $20 million Series B Preferred Stock private placement financing. This financing was led by new investor, AgeChem Venture Fund of Montreal, Canada, and included participati... |
| 11.02.2011 | Conatus Pharmaceuticals Closes $20M Series B Financing | Conatus Pharmaceuticals Inc., a San Diego, CA-based biopharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology, closed a $20m Series B financing. This round, which will remain o... |
| 11.02.2011 | Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing | SAN DIEGO – Conatus Pharmaceuticals Inc. today announced the closing of a $20 million Series B Preferred Stock private placement financing. This financing was led by new investor, AgeChem Venture Fund of Montreal, Canada, and included parti... |
| 11.05.2007 | Inflammation drug maker Conatus Pharma completes $27.5M round | Conatus Pharmaceuticals, a San Diego developer of drugs for inflammation and liver disease, closed a $22 million private placement that brings its first round of funding to $27.5 million. Investors included Aberdare Ventures, Advent Venture... |
Show more